103 related articles for article (PubMed ID: 2230890)
1. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience.
Hudson M; Jaffe MR; Jaffe N; Ayala A; Raymond AK; Carrasco H; Wallace S; Murray J; Robertson R
J Clin Oncol; 1990 Dec; 8(12):1988-97. PubMed ID: 2230890
[TBL] [Abstract][Full Text] [Related]
2. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma: review of the past, impact on the future. The American experience.
Jaffe N
Cancer Treat Res; 2009; 152():239-62. PubMed ID: 20213394
[TBL] [Abstract][Full Text] [Related]
4. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
[TBL] [Abstract][Full Text] [Related]
5. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
6. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival.
Jaffe N; Spears R; Eftekhari F; Robertson R; Cangir A; Takaue Y; Carrasco H; Wallace S; Ayala A; Raymond K
Cancer; 1987 Feb; 59(4):701-9. PubMed ID: 3492261
[TBL] [Abstract][Full Text] [Related]
7. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
10. Control of primary osteosarcoma with chemotherapy.
Jaffe N; Robertson R; Takaue Y; Cangir A; Wallace S; Carrasco H; Eftekhari F; Ayala A; Wang A
Cancer; 1985 Aug; 56(3):461-6. PubMed ID: 3873985
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma.
Jaffe N; Robertson R; Ayala A; Wallace S; Chuang V; Anzai T; Cangir A; Wang YM; Chen T
J Clin Oncol; 1985 Aug; 3(8):1101-4. PubMed ID: 3874932
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma.
Liu Y; Xu Y; Lin N; Jiang S; Wang Y; Ye Z
Cell Biochem Biophys; 2015 Mar; 71(2):1097-104. PubMed ID: 25417058
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers PA; Heller G; Healey J; Huvos A; Lane J; Marcove R; Applewhite A; Vlamis V; Rosen G
J Clin Oncol; 1992 Jan; 10(1):5-15. PubMed ID: 1370176
[TBL] [Abstract][Full Text] [Related]
15. Increased survival, limb preservation, and prognostic factors for osteosarcoma.
Petrilli AS; Gentil FC; Epelman S; Lopes LF; Bianchi A; Lopes A; Figueiredo MT; Marques E; De Bellis N; Consentino E
Cancer; 1991 Aug; 68(4):733-7. PubMed ID: 1855172
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy in the treatment of osteosarcoma of the extremities: preliminary results in 131 cases treated preoperatively with methotrexate and cisdiamminoplatinum.
Bacci G; Avella M; Capanna R; Boriani S; Dallari D; Galletti S; Giunti A; Madon E; Mancini A; Mercuri M
Ital J Orthop Traumatol; 1988 Mar; 14(1):23-39. PubMed ID: 3235324
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
[TBL] [Abstract][Full Text] [Related]
18. High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II.
Jaffe N; Frei E; Traggis D; Cassady JR; Watts H; Filler RM
Cancer Treat Rep; 1977 Jul; 61(4):675-9. PubMed ID: 301780
[TBL] [Abstract][Full Text] [Related]
19. [Adjuvant chemotherapy of osteosarcoma].
Yamawaki S; Isu K; Ubayama Y; Takeda N; Yagi T; Usui M; Isii S
Gan To Kagaku Ryoho; 1990 Feb; 17(2):180-8. PubMed ID: 2301948
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
